Trivium Point Advisory LLC Invests $1.48 Million in Boston Scientific Corporation $BSX

Trivium Point Advisory LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 34,578 shares of the medical equipment provider's stock, valued at approximately $1,476,000.

A number of other institutional investors have also added to or reduced their stakes in BSX. Norges Bank purchased a new position in shares of Boston Scientific in the 4th quarter worth approximately $2,199,395,000. Bank of New York Mellon Corp purchased a new position in Boston Scientific in the second quarter worth $339,031,000. Assenagon Asset Management S.A. boosted its position in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider's stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the last quarter. Janus Henderson Group PLC grew its stake in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares during the period. Finally, Maverick Capital Ltd. bought a new position in Boston Scientific in the 4th quarter valued at $280,735,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Down 0.1%

Shares of BSX opened at $51.77 on Monday. The business's 50-day moving average price is $46.06 and its 200-day moving average price is $59.11. The stock has a market cap of $75.02 billion, a PE ratio of 20.96, a P/E/G ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the company's stock in a transaction dated Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 204,322 shares of company stock worth $9,939,221. 0.34% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BSX shares. Daiwa Securities Group lowered shares of Boston Scientific from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Raymond James Financial reiterated an "outperform" rating and issued a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Bank of America reduced their price objective on Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a report on Monday, May 18th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source